Vascular endothelial growth factor in patients with psoriatic arthritis

Clinical and Experimental Rheumatology

Volumn 25, Issue 2, 2007, Pages 305-308

  Fink, Astrid M ^c   Cauza, Edmund ^c   Hassfeld, Wolfgang ^a   Dunky, Attila ^a   Bayer, Peter M ^b   Jurecka, Wolfgang ^c   Steiner, Andreas ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c Department of Dermatology ^*  (Austria)

Author keywords

Disease activity; Psoriatic arthritis; Vascular endothelial growth factor

Indexed keywords

C REACTIVE PROTEIN; VASCULOTROPIN 165;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY OF LIFE; VISUAL ANALOG SCALE;

ADULT; AGED; ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34249774013     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. STEM RS: Epidemiology of cutaneous disease. In FITZPATRICK TB (Ed.): Textbook of General Medicine, New York, McGraw Hill, 1987: 6-10.
2. TUNN EJ, BACON PA: Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993; 32: 97-103.
3. CARMELIET P, JAIN RK: Angiogenesis in cancer and other disease. Nature 2000; 407: 249-57.
4. BRAVERMAN IM, YEN A: Microcirculation in psoriatic skin. J Invest Dermatol 1974; 62: 493-502.
5. BRAVERMAN IM, YEN A: Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 1977; 68: 53-60.
6. HULL S, GOODFIELD M, WOOD EJ, CUNLIFFE WJ: Active and inactive edges of psoriatic plaques: Identification by tracing and investigation by laser-Doppler flowmetry and immunocytochemical techniques. J Invest Dermatol 1989; 92: 782-5.
7. VEALE D, ROGERS S, FITZGERALD O: Immunolocalization of adhesion molecules in psoriatic arthritis, psoriatic and normal skin. Br J Dermatol 1995; 132: 32-8.
8. GRIFFITHS CE, VOORHEES JJ, NICKOLOFF BJ: Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: Modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 1989; 20: 617-29.
9. CREAMER D, JAGGAR R, ALLEN M, BICKNELL R, BARKER J: Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/ thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 1997; 137: 851-5.
10. VEALE D, YANNI G, ROGERS S, BARNES L, BRESNIHAN B, FITZGERALD O: Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Rheum 1993; 36: 893-900.
11. DETMAR M, BROWN LF, CLAFFEY KP et al.: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptor in psoriasis. J Exp Med 1994; 180; 1141-6.
12. REECE RJ, CANETE JD, PARSONS WJ, EMERY P, VEALE DJ: Distinct vascular patterns in the synovitis in psoriatic, reactive and rheumatoid arthritis. Arthritis Rheum 1999; 42: 1481-5.
13. ESPINOZA LR, VASEY FB, ESPINOZA CG, BOCANEGRA TS, GERMAIN BF: Vascular changes in psoriatic synovium: A light and electron microscopic study. Arthritis Rheum 1982; 25: 677-84.
14. YANCOPOULOS GD, DAVIS S, GALE NW, RUDGE JS, WIEGAND SJ, HOLASH J: Vascular specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
15. FERRARA N: Vascular endothelial growth factors and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55: 15-35.
16. ACHEN MG, STACKER SA: The vascular endothelial growth factor family: proteins which guide the development of the vasculature. Int J Exp Pathol 1998; 79: 255-65.
17. ASAHARA T, CHEN D, TAKAHASHI T et al.: Tie 2 receptor ligands angiopoietin - and angiopoietin-2, modulate VEGF-induced post-natal neovascularization. Circ Res 1998; 83: 233-40.
18. SURI C, MCCLAIN J, THURSTON G et al.: Increased vascularization in mice overexpression angiopoietin 1. Science 1998; 282: 468-71.
19. HOLASH J, MAISONPIERRE PC, COMPTON D et al.: Vessel cooption regression and growth in tumors mediated by angiopoietin and VEGF. Science 1999; 284: 1994-8.
20. CREAMER D, ALLEN M, JAGGAR R, STEVENS R, BICKNELL R, BARKER J: Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 2002; 138: 791-6.
21. ETTEHADI P, GREAVES MW, WALLACH D, ADERKA D, CAMP RD: Elevated tumour necrosis factor alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-51.
22. ELDER JT, FISHER GJ, LINDQUIST PB et al.: Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 1989; 243: 811-4.
23. BHUSHAN M, MCLAUGHLIN B, WEISS JB, GRIFFITHS CE: Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999; 141: 1054-60.
24. NIELSEN HJ, CHRISTENSEN IJ, SVENDSEN MN et al.: Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 2002; 51: 563-7.
25. FEARON U, GRIOSIOS K, FRASER A et al.: Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003; 30: 260-8.
26. DROUART M, SAAS P, BILLOT M et al.: High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 2003; 132: 158-62.
27. BALLARA S, TAYLOR PC, REUSCH P et al.: Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001; 44: 2055-64.
28. MOLL JMH, WRIGHT V: Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78.
29. VASEY FB, ESPINOZA LR: Psoriatic arthritis. In CALIN A (Ed.): Spondyloarthropathies, Orlando, Grune and Stratton, 1984: 151-85.
30. HELLIWELL PS, TAYLOR WJ: Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005; 64 (Suppl. 2): 3-8.
31. TAYLOR W, GLADMAN D, HELLIWELL P, MARCHESONI A, MEASE P, MIELANTS H: CASPAR Study Group Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
32. KAVANAUGH A, CASSELL S: The assessment of disease activity and outcomes of psoriatic arthritis. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S142-7.
33. MEASE PJ, GOFEE BS, METZ J, VAN DER STOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000; 356: 385-90.
34. BLACKMORE MG, GLADMAN DD, HUSTED J, LONG JA, FAREWELL VT: Measuring health status in psoriatic arthritis: The Health Assessment Questionnaire and its modification. J Rheumatol 1995; 22: 886-93.
35. MAENO N, TAKEI S, IMANAKA H et al.: Increased circulating vascular endothelial growth factor is correlated with disease activity in polyarticular juvenile arthritis. J Rheumatol 1999; 26: 2244-8.
36. PALEOLOG EM, YOUNG S, STARK AC, MCCLOSKEY RV, FELDMANN M, MAINI RN: Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1258-65.
37. KLIMIUK PA, STERAKOWSKIS S, DOMYSLAWSKA I, FLEDORCZYK M, CHWIECKO J: Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1 and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp 2004; 52: 36-42.
38. STRUNK J, BUNDKE E, LANGE U: Anti-TNF alpha antibody infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis. A pilot study. Rheumatol Int 2006; 26: 252-6.
39. MASTROIANNI A, MINUTILLI E, MUSSI A et al.: Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 2005; 153: 531-6.
40. MACIAS I, GARCIA-PEREZ S, RUIZ-TUDELA MR, MEDINA F, CHOZAS N, GIRON-GONZALEZ JA: Modification of pro- and antiinflammatory cytokines and vascular related molecules by tumor necrosis factor - a blockade in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 2102-8.